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an-Xin Yan, MD, PHD†
ynnewood and Philadelphia, Pennsylvania
recise information regarding prolongation of cardiac repo-
arization by non-cardiac drugs has become a highly valued
ommodity. The reason for this emphasis is that we now
now that chemical entities that have the propensity to
rolong repolarization may, under some set of circum-
tances, cause a particularly malignant form of ventricular
rrhythmia called Torsade de Pointes (TdP). With rare
xceptions, a relationship appears to exist between the
agnitude of prolongation of ventricular refractoriness and
he risk of developing TdP. To this point in time, the
linical parameter that has been used to measure changes in
efractoriness has been the QT interval. To some extent, its
se is ironic because there has been general consensus
See page 678
mong experts in the field of electrophysiology that the QT
nterval is a relatively poor indicator of repolarization
hanges (1–3). Many reasons exist for this lack of support
mong experts, including difficulties in making precise
easurements, the effects of heart rate modulation, and
ntrasubject and intersubject variability. Nevertheless, as bad
s it is, the QT interval remains the only clinically available
arameter that can be applied practically and realistically to
he large population of patients that need to be evaluated
ot only in clinical trials but, even more importantly, in
linical practice.
So what has been done to improve on the “sow’s ear” of
he QT interval to glean more precise information about
entricular repolarization? This has proven to be a sticky
icket. There have been a number of strategies, including
ttempts to measure interlead QT dispersion, quantification
f portions of the T-wave, such as T-peak to T-end, and
uantification of alternations in T-wave voltage (2,4–6). To
ate, none of these have satisfied our need for a reliable
on-invasive measurement of abnormal repolarization. The
dea that has been promulgated by regulatory agencies has
een to increase the reliability of the measurement of the
T interval itself by standardizing methods and by multi-
lying the number of observations to reduce variability.
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From the †Main Line Health Heart Center, Wynnewood, and ‡Thomas Jefferson
niversity, Philadelphia, Pennsylvania.nother important component of this refined methodology
s to “calibrate the assay” by including a positive comparator
n what has been referred to as “a definitive QT study.” The
nference is that the demonstration of a small increase in the
T interval with a drug that has a well-defined effect on
entricular repolarization provides a measure of assurance
hat the techniques of QT measurement that were used in
hat particular experiment were adequate to arrive at satis-
actory conclusions about the innovator drug. Specifically,
raft guidances have stated that positive comparators chosen
hould be agents that are known to consistently prolong the
T interval by approximately 5 ms or less because this is the
argest change that is currently viewed as clinically not
mportant and not likely to relate to TdP. The drug that has
een used most frequently for this purpose has been oral
oxifloxacin, usually given at a dose of 400 mg orally.
In this issue of the Journal, Beasley et al. (7) report the
esults of a study aimed at defining the QT-prolonging
ffects of oral tadalafil, an inhibitor of phosphodiesterase-5
hat is indicated for the treatment of erectile dysfunction.
rugs in this particular class have been shown to have a
eak effect on repolarizing currents preclinically but have
ot been shown to have a significant effect on the QT
nterval or to cause TdP. Nevertheless, excluding a QT-
rolonging effect of tadalafil was an integral part of the
egulatory approval of that drug, as it is for any new
hemical entity. However, the major point of scientific
nterest in this regulatory-grade study was the use of a novel
ositive comparator, ibutilide. At first blush, ibutilide, given
ts known powerful effect on ventricular repolarization,
eems to have been an odd choice for this purpose. How-
ver, on closer inspection, the use of ibutilide was conscio-
able and reasonable. The drug was delivered in such a way
s to produce reproducibly small amounts of QT-interval
rolongation and, thus, it satisfactorily validated the test
rocedure. The study was conducted safely, with no in-
tances of ventricular arrhythmia or excessive QT-interval
rolongation, although in some patients the infusion did
ave to be discontinued for safety reasons.
Although the study achieved its primary objective, there
re a few caveats that are worth emphasis. First, the study
hat was reported here was impressive in scope. More than
4,000 electrocardiograms were collected, interpreted, ana-
yzed, and reported and this included intensive baseline
ampling. This collection represents a significant expense
or one relatively small clinical study. Although it was
uccessful, we should not be satisfied to let this kind of study
ecome the permanent standard for assessing the risk of
dP by a new chemical entity. We need to continue to
earch for cheaper and easier and more precise methods that
ight even provide definitive information about what we
eally care about, which is the risk of TdP.
Second, ibutilide is a potentially harmful drug. As the
uthors point out, there is danger inherent in using any drug
hat prolongs the QT interval, and it is true that ibutilide
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evertheless, subjects need to be fully informed of the risks
f using ibutilide. Facilities for prompt resuscitation have to
e in place together with the expertise to monitor the QT
nterval carefully so that the infusion can be stopped and
agnesium administered when appropriate, as was the case
n this study. It also should be remembered that the use of
n intravenous medication in the study of an oral drug raises
istinct problems with blinding and bias that can influence
he results. Blinded interpretation of the electrocardio-
rams, as was performed in the current study, mitigates
ost but not all of this concern.
Finally, this experiment sought to identify a latent effect
f tadalafil or ventricular repolarization by exposing normal
ndividuals to supratherapeutic doses of the drug. This
ethodology has become accepted on the basis of sound
harmacokinetic and pharmacodynamic principals. How-
ver, whether these results will truly predict TdP in the real
arget population that comprises patients with heart disease,
ncluding some with repolarization variants and those with
ubclinical gene mutation or ion channel polymorphism
3,8,9), is yet to be proven conclusively.
Beasley et al. (7) are to be congratulated for attempting to
mprove on a methodology that has been put into place,
ndorsed by regulators, and embraced by industry for
earning about the safety of non-cardiac drugs. However, for
ll of the science and logic, QT-interval prolongation is a
oor surrogate for a lethal arrhythmia that happens rarely
nd is catastrophic. It can be argued that any drug that
rolongs the QT interval to any extent may under some
ircumstances cause TdP in someone, somewhere, some-
ime. Clearly, the challenge is to identify patients at risk in
more precise way and to couple that kind of risk assess-
9ent with a more precise quantification of the proarrhyth-
ic potential of drugs, especially when their indication is a
alady that itself does not threaten life. Trying to convert
he “sow’s ear” of QT-interval measurement into a “silk
urse” of risk stratification is unlikely to be the final
olution, but for now it is all that we can do.
eprint requests and correspondence: Dr. Peter R. Kowey, Suite
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ewood, Pennsylvania 19096. E-mail: koweypr@mlhheart.org.
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